Bimekizumab Versus Ustekinumab in Plaque Psoriasis: Lasting Efficacy Translates to Rapid and Sustained Improvements in Quality of Life in the BE VIVID Multicenter, Randomized, Double-Blinded Phase 3 Trial

Main Article Content

K Gordon
P Foley
P Rich
K Duffin
A Pinter
CEM Griffiths
M Wang
V Vanvoorden
F Staelens
V Ciaravino
JF Merola

Keywords

Plaque Psoriasis, Bimekizumab, Ustekinumab, Biologic, Quality of Life, Efficacy

Abstract

Abstract not available.

References

1. Bhosle MJ. Health Qual Life Outcomes 2006;4:35

2. Glatt S. Br J Clin Pharmacol 2017;83:991–1001

3. Papp KA. J Am Acad Dermatol 2018;79:277–86.e10

4. Durham L. Curr Rheumatol Rep 2015;17:55

5. Fujishima S. Arch Dermatol Res 2010;302:499–505

6. Mahil SK. Br J Dermatol 2020;182:1158–66

7. Hongbo Y. J Invest Dermatol 2005;125:659–64.
Author Contributions